Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.

Headache·2021

Same author

Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.

Circulation·2021

Same author

Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.

Cephalalgia : an international journal of headache·2021

Same author

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.

Journal of arrhythmia·2021

Same author

MMW Fortschritte der Medizin·2021

Same author

COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany.

Annals of neurology·2021

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelet agents and randomized trials.

Hans-Christoph Diener¹

¹Department of Neurology, University Dusiburg-Essen, Essen, Germany.

Reviews in Neurological Diseases

|January 16, 2008

Summary

Patients experiencing transient ischemic attack (TIA) or stroke face high recurrent event risks. Effective secondary prevention strategies, including antithrombotic therapies, are crucial for reducing stroke recurrence and improving outcomes.

Area of Science:

Neurology
Cardiology
Vascular Medicine

Background:

Transient ischemic attack (TIA) and ischemic stroke patients have a significant annual risk (5-15%) of recurrent stroke.
This risk is acutely elevated within 48 hours of TIA and 7 days of ischemic stroke.
Secondary stroke prevention encompasses antithrombotic therapy, risk factor management, and carotid stenosis intervention.

Purpose of the Study:

To review antithrombotic treatment options for secondary stroke prevention.
To compare the efficacy and safety of various antiplatelet therapies.
To highlight ongoing research in optimizing secondary stroke prevention strategies.

Main Methods:

Review of clinical trials and guidelines on antithrombotic therapies.
Comparison of aspirin monotherapy, aspirin plus extended-release dipyridamole (ER-DP), clopidogrel, and clopidogrel plus aspirin.

Related Experiment Videos

Last Updated: Jul 8, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Discussion of oral anticoagulation for specific patient populations (e.g., atrial fibrillation).

Main Results:

Aspirin monotherapy provides modest risk reduction for recurrent stroke and major vascular events.
Aspirin plus ER-DP demonstrates superiority over aspirin monotherapy.
Clopidogrel is more effective than aspirin in high-risk patients with stroke, MI, or peripheral arterial disease.
Clopidogrel plus aspirin combination therapy shows no added benefit over monotherapy and increases bleeding risk, though potential short-term benefits are noted.

Conclusions:

Combination therapy with clopidogrel and aspirin is not recommended for routine secondary stroke prevention due to increased bleeding risk.
Aspirin plus ER-DP is a superior alternative to aspirin monotherapy for secondary stroke prevention.
Further research, including ongoing trials comparing aspirin plus ER-DP with clopidogrel, is essential for refining secondary stroke prevention strategies.